NIH awards $4.6M for trial of skin substitute

Madison, Wis.-based Stratatech received a $4.6 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases to test safety and efficacy of the company's ExpressGraft antimicrobial skin substitute in patients with chronic diabetic foot ulcers. The genetically engineered cell-based product fights infection and accelerates healing, according to Stratatech.

View Full Article in:

Milwaukee Journal Sentinel (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Executive Officer
UCare Minnesota
Minneapolis, MN